Conditions: Colon Cancer; PCSK9 Inhibitor; Neoadjuvant Immunochemotherapy
Interventions: Drug: Tafolecimab; Drug: Sintilimab
Sponsors: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University; Shapingba District People’s Hospital; The Second Affiliated Hospital of Chongqing Medical University; Jiangbei Campus of The First Affiliated Hospital of Army Medical University (Army 958 Hospital); Third Affiliated Hospital of Chongqing Medical University; Chongqing Yongchuan District People’s Hospital, Deyang People’s Hospital; Guang’an People’s Hospital, Kaizhou District People’s Hospital; 940 Hospital of the People’s Liberation Army Joint Logistic Support Force
Recruiting Conditions: Colon Cancer; PCSK9 Inhibitor; Neoadjuvant Immunochemotherapy
Interventions: Drug: Tafolecimab; Drug: Sintilimab
Sponsors: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University; Shapingba District People’s Hospital; The Second Affiliated Hospital of Chongqing Medical University; Jiangbei Campus of The First Affiliated Hospital of Army Medical University (Army 958 Hospital); Third Affiliated Hospital of Chongqing Medical University; Chongqing Yongchuan District People’s Hospital, Deyang People’s Hospital; Guang’an People’s Hospital, Kaizhou District People’s Hospital; 940 Hospital of the People’s Liberation Army Joint Logistic Support Force
Recruiting
